Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. - Wikidata - wikimedia - TriplyDB

Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy.

Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy.

http://www.wikidata.org/entity/Q33406032

about

Advances in Diagnosis and Treatments for Immune Thrombocytopenia Long-term safety and efficacy of romiplostim for treatment of immune thrombocytopenia Current Management of Primary Immune Thrombocytopenia Use of Thrombopoietin Receptor Agonists in Childhood Immune Thrombocytopenia Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review Eltrombopag for the treatment of aplastic anemia: current perspectives Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study.The efficacy and safety of romiplostim in adult patients with chronic immune thrombocytopenia.Immune thrombocytopenia -- what are the new treatment options?The biology of thrombopoietin and thrombopoietin receptor agonists.Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials.Contemporary treatment of immune thrombocytopenia.Romiplostim in children with chronic immune thrombocytopenia (ITP): the French experience.Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up.Milestones in understanding platelet production: a historical overview.Novel treatments for immune thrombocytopenia.Successful platelet count recovery in lupus-associated thrombocytopenia with the thrombopoietin agonist eltrombopag.A review of the management of childhood immune thrombocytopenia: how can we provide an evidence-based approach?Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors.Management of thrombocytopenia.Impact of self-administration of romiplostim by patients with chronic immune thrombocytopenia compared with administration by a healthcare provider.Thrombopoietin levels in systemic lupus erythematosus are linked to inflammatory cytokines, but unrelated to thrombocytopenia or thrombosis.Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP).Immunosuppressive treatment combined with nucleoside analog is superior to nucleoside analog only in the treatment of severe thrombocytopenia in patients with cirrhosis associated with hepatitis B in China: A multicenter, observational study.Romiplostim as a treatment for immune thrombocytopenia: a review.Thrombopoiesis-stimulating agents and myelodysplastic syndromes.Antibody binding to megakaryocytes in vivo in patients with immune thrombocytopenia.Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia.Feasibility of romiplostim discontinuation in adult thrombopoietin-receptor agonist responsive patients with primary immune thrombocytopenia: an observational retrospective report in real life clinical practice.Romiplostim in the management of the thrombocytopenic surgical patient.Refractory immune thrombocytopenia. Successful treatment with repeated cyclosporine A: two case reports.Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim.Case study of remission in adults with immune thrombocytopenia following cessation of treatment with the thrombopoietin mimetic romiplostim.Signal for Thrombosis with Eltrombopag and Romiplostim: A Disproportionality Analysis of Spontaneous Reports Within VigiBase®.Efficacy and safety of the thrombopoietin receptor agonist romiplostim in patients aged ≥ 65 years with immune thrombocytopenia.Effect of a thrombopoietin receptor agonist on use of intravenous immune globulin in patients with immune thrombocytopenia.Evaluation of romiplostim for the treatment of secondary failure of platelet recovery among allogeneic hematopoietic stem cell transplant patients.Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study.Is ITP a thrombophilic disorder?The Effect of Danazol in Primary Immune Thrombocytopenia: An Analysis of a Large Cohort From a Single Center in China.

P2860

Q26738630-6CD9A652-C76C-4B22-A29B-572E60524D8F Q26745753-8955550D-D7CB-4284-B17F-05E393B9E1EE Q26779408-E809D3EF-2D1D-4DEB-AC1B-AB5B5910C40F Q26795730-5751EB1E-4E5E-4523-99C7-A725B810403F Q26826853-75CAC6D3-9120-459D-A4E9-4B5BE797A592 Q28071710-6CF41C41-90E5-4020-9B27-8BB0F710D5D6 Q31089024-CF9F0BC2-60EF-48EE-B64A-DB6E2AE4CDB6 Q33407279-BBD4BF17-FBE7-4EB8-B4E0-FD439F0A55FD Q33407802-163460E4-AAF0-4F14-A8B6-2F0D43BCAAC4 Q33408850-98333CCD-2FCF-4825-AD25-C127188F9199 Q33409611-311B62F4-591F-49E9-BFD0-1D41109D80CD Q33410653-AC9B9C38-125C-4E56-87AB-7223B80B0E7F Q33411082-F054BF86-1C1F-4441-A4A0-19498A186333 Q33412896-E6AFE370-E6F3-4181-BFAE-221CD9CCD19C Q33413326-61B5804A-D896-422D-980F-CC6DBD9D161E Q33414132-974224AD-4C18-4A73-A7E2-1B911144CF9C Q33414666-9D7B7DDB-EDF6-425C-BA53-D552D495C901 Q33414825-CAA891B2-67E3-49DD-82F8-3EFFEDB2ACD8 Q33415996-C9A8ADBF-2A18-4FB1-900F-A26C0C18B42E Q33416258-EAB865D4-CFAA-4FFE-BB11-5DE2BC49AB59 Q33416547-0191CD67-56F0-42AF-89A7-7671C80F3F51 Q33417017-DD49FFC2-619E-4230-9DEB-DF1CB602EB78 Q33418391-66C4F03B-4B7F-4D96-8479-79A9F7B2E5E9 Q33418708-CBA1A130-2320-47ED-AA14-6DD81629D6A3 Q33420059-53D6915B-3C4D-488F-AFB1-ED61D2A48285 Q33420207-4E4BD0FC-0102-4245-AE95-AD4B71E748F4 Q33420459-3965B023-9C25-4444-9848-8C1F7397A5EA Q33421634-72EAA60B-5419-48F1-9A80-F8BBCCBAF2DC Q33421783-5502FFDF-378B-4DFA-ABE3-17AD719D36AA Q33423291-532319D6-A7E4-4587-9681-83A19F3CF21B Q33424554-270D7D9A-3AE9-46B9-81E3-EC3018B0629F Q33424664-59228BFC-0496-4CD6-B311-DA944EBD05B8 Q33425012-883A611C-9374-42A3-AB0F-1C23B33E491B Q33425628-DECC0BC6-AA07-4C95-AEFA-89B2F4F19248 Q33425644-CB13C25A-3A29-4197-ABF1-2550B1E119F5 Q33426166-EEEE12F2-6987-424E-9557-4D92C9123032 Q33426772-195D5182-2C49-4978-B450-34E18A8EA98D Q33427336-0C845334-4A6C-423D-B7E3-CC3795A4227F Q33427394-38FBB59D-5DD4-4902-B024-2A7D04EFF8C7 Q33428522-C996D539-0168-40C4-ADAE-D4419E524E61

P2860

Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy.

http://www.wikidata.org/entity/Q33406032

description

2013 nî lūn-bûn

@nan

2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Long-term treatment with romip ...... ytopenia: safety and efficacy.

@ast

Long-term treatment with romip ...... ytopenia: safety and efficacy.

@en

type

label

Long-term treatment with romip ...... ytopenia: safety and efficacy.

@ast

Long-term treatment with romip ...... ytopenia: safety and efficacy.

@en

prefLabel

Long-term treatment with romip ...... ytopenia: safety and efficacy.

@ast

Long-term treatment with romip ...... ytopenia: safety and efficacy.

@en

P1433

Q33406032-0FCE9EDE-5094-4062-BBB1-8B400CB7AE92

P1476

Q33406032-5BC075C3-8356-494E-9F01-AF41AB7CAEFC

P2093

Q33406032-38613373-40C6-4073-BD90-E2352CABD43E

Q33406032-3968ACA5-246E-471B-8DFD-B9A9F06E3201

Q33406032-4019BD76-9152-44F1-A92E-295BAB08E1AC

Q33406032-706D589D-AE45-4A1C-B914-607DE20ED1E4

Q33406032-8A5AA4E5-9F4B-41B5-AB3A-EFCA96C231B5

Q33406032-8E0545D6-53D7-4B2E-A592-AE6F596CDC02

Q33406032-958CDC0B-3639-4C88-B0F9-A34B57AC3503

Q33406032-B8D497F8-05D1-45BB-BCE6-425B60A44C04

Q33406032-C782BCD7-3348-4074-A553-37DB41BD63FF

Q33406032-DAAF70C1-D4BD-4DEC-978D-B9A367853D50

P2860

Q33406032-000D4ED3-2BE2-4AB0-A5BE-426D1AF85817

Q33406032-07B2FBB9-6CA2-433C-9D9D-DB1A8B0C95BD

Q33406032-0FD2CB6E-2BA8-493A-B405-6F43F36CFE54

Q33406032-1E473282-834C-48A4-A231-E99FC4BB9F9B

Q33406032-2DC4306F-05CF-4410-8FDB-A9CAC20B4887

Q33406032-342ABBA3-69E6-41CE-BBE0-F14419E0E9FD

Q33406032-5BC7CF08-DC79-4733-BCA1-589CF4127E1C

Q33406032-5D755A54-A0B9-4F65-BADB-415B82B0A331

Q33406032-62A9D1BE-5229-4F34-BC47-DD25B6692AE5

Q33406032-67236A9C-8E0C-406D-965E-0006AE416BF7

P304

Q33406032-C89069E2-B3E3-40AA-AC3C-D323AE6AF9BD

P31

Q33406032-E6DE2B68-0270-44EC-9A7C-1DA5173D91D3

P356

Q33406032-5339D990-CE6B-4FFB-B5D2-5DB395E4DDFB

P407

Q33406032-49A31355-A45B-43E8-B8F1-28C18CCB7BC5

P433

Q33406032-28C6F2D3-80FC-4749-A162-8C99A4765C44

P478

Q33406032-CB0D3152-62D1-4D13-B25F-351DDD4B8873

P50

Q33406032-E83A65E0-3621-406E-8BAB-DF5FEC76DC7A

P577

Q33406032-4A5C1C05-7E73-47AD-96B3-19240C065670

P698

Q33406032-4E695747-3DC6-4924-9761-51F107A178D0

P921

Q33406032-83AE0965-49B5-4D37-AD95-527CDEF3C478

P356

P1433

British Journal of Haematology

P1476

Long-term treatment with romip ...... ytopenia: safety and efficacy.

@en

P2093

Adrian Newland

http://www.w3.org/2001/XMLSchema#string

David J Kuter

http://www.w3.org/2001/XMLSchema#string

Gail Macik

http://www.w3.org/2001/XMLSchema#string

Jean-Francois Viallard

http://www.w3.org/2001/XMLSchema#string

Jeffrey Wasser

http://www.w3.org/2001/XMLSchema#string

Kun Nie

http://www.w3.org/2001/XMLSchema#string

Mathias Rummel

http://www.w3.org/2001/XMLSchema#string

Roger M Lyons

http://www.w3.org/2001/XMLSchema#string

Ross I Baker

http://www.w3.org/2001/XMLSchema#string

Susie Jun

http://www.w3.org/2001/XMLSchema#string

P2860

International consensus report on the investigation and management of primary immune thrombocytopenia

The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia

Thrombocytopenia caused by the development of antibodies to thrombopoietin.

Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro.

Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP.

How I treat idiopathic thrombocytopenic purpura (ITP).

AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP.

An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura.

The immune thrombocytopenic purpura (ITP) bleeding score: assessment of bleeding in patients with ITP.

Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.

P304

411-423

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJH.12260

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

161

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-02-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23432528

http://www.w3.org/2001/XMLSchema#string

P921

thrombocytopenia